Introduction
Yersinia pestis, the agent of plague, is one of a limited number of organisms that are regarded as serious potential bioterrorism or biowarfare threats. 1 Y. pestis is a zoonotic pathogen which currently causes naturally-acquired plague in a number of countries around the world. The reservoir is principally rodents of various species, and transmission is usually flea-borne. It is amenable to mass production and aerosol dispersion (thus bypassing the need for flea vectors) and is highly infectious in this form. It is well known that several nations actively pursued research into the development of bioweapons utilizing Y. pestis in recent decades. 1, 2 Untreated primary pneumonic plague has a high mortality, and it has been estimated that 50 kg of aerosolized Y. pestis, released over a city of 5 million, would cause up to 150 000 cases of pneumonic plague, of whom 36 000 might be expected to die. 3 Apart from the actual deaths which would occur in this scenario, it is likely that there would be widespread civil disruption and general panic, as occurred during the natural outbreak of urban plague in Surat, India, in 1994. 4 For many decades, reliance has been placed on a limited number of antibiotics for treatment and prophylaxis of plague. Only streptomycin and tetracycline or doxycycline are approved for this purpose by the Food and Drug Administration (FDA) of the United States; however, due to limited availability of streptomycin, gentamicin is often successfully substituted. 1 Chloramphenicol has been advocated for treatment of plague meningitis because of good meningeal penetration, but this has not been tested in human clinical trials. Sulphonamides and trimethoprim-sulfamethoxazole are usually regarded as second-line choices for management of plague. 1 There is in vitro and animal experiment evidence for efficacy of fluoroquinolones, 5, 6 but clinical trials have not been carried out. The United States Working Group on Civilian Biodefense recommended streptomycin or gentamicin as the preferred choice in a contained casualty setting (i.e. modest numbers of patients requiring treatment), with doxycycline, ciprofloxacin, or chloramphenicol as alternative choices. For a mass casualty situation, the US Working Group recommended oral therapy with doxycycline or tetracycline, or ciprofloxacin. 1 Novel ketolide and penem antimicrobials have previously shown potentially useful in vitro activities, 5 and we now report on further susceptibility studies in clinical isolates of Y. pestis.
Materials and methods

Yersinia pestis isolates and control organisms
The 28 strains of Y. pestis were human blood culture isolates from a plague focus in northern Namibia, isolated between 1982 and 1991. Isolates had been stored in semi-solid agar; purity was checked by plating 
Antibiotics tested
Clarithromycin, erythromycin, cefdinir, cefditoren, ciprofloxacin, temafloxacin, tosufloxacin and the experimental agents cethromycin (ABT 773, a ketolide), olamufloxacin (HSR 903) and ABT 492 (fluoroquinolones), were all obtained from Abbott Laboratories, Abbott Park, IL, USA. Doxycycline was supplied by Sigma (S. Africa), Midrand, South Africa.
Determination of antimicrobial susceptibility
All work was done in a class 2 biosafety cabinet in the biosafety level 3 laboratory of the National Health Laboratory Service, Johannesburg, South Africa. We used the agar dilution method to determine MICs, according to the method of the National Committee for Clinical Laboratory Standards (NCCLS), 7 with the following minor modifications: for safety reasons all culturing of Y. pestis was done at 28°C, as its Fraction 1 capsular virulence factor is not produced at this temperature, and growth was assessed at 18-20 h (controls) and at 48 h (Y. pestis). Inocula of Y. pestis were prepared by suspending 18-to 20-h colonies in trypticase soy broth, and adjusting the turbidity to the equivalent of a 0.5 McFarland standard. The MICs at which 50% and 90% of isolates were inhibited (MIC 50 and MIC 90 , respectively) were determined.
Results and discussion
Results of antimicrobial testing are shown in Table 1 . The MICs for the control organisms were within the expected ranges for previously characterized antibiotics. 7 Cefditoren and the fluoroquinolones, both novel and conventional, showed excellent activity against the Y. pestis strains tested. Likewise, in our previous study which tested a larger number of isolates (n = 100), the most active agents were the extended spectrum cephalosporin cefotaxime, and the fluoroquinolones levofloxacin and ofloxacin. 5 Although extended-spectrum cephalosporins showed good efficacy in experimental murine septicaemic plague, 6 a mouse pneumonic plague model suggested that β-lactam antibiotics are not sufficiently active for treatment purposes, 8 and none are currently recommended for human plague management. 1, 8 The efficacy of fluoroquinolones has been demonstrated in a mouse model of plague 6 and our data support further investigation of quinolones ABT 492 and olamufloxacin (HSR 903) in animal experiments. Not surprisingly, the in vitro activity of macrolides was poor against this member of the Enterobacteriaceae. The ketolide cethromycin (ABT 773) showed enhanced activity compared to the macrolides, but was less active than telithromycin. 5 Antibiotic resistance has not proved to be a major problem in naturally occurring plague, but as in the case of anthrax and other bacterial biowarfare threats, there is the potential for production of resistant strains. Isolates of Y. pestis showing tetracycline resistance or reduced susceptibility to streptomycin have been described in some African countries and rare plasmidmediated multidrug-resistant isolates have been reported from Madagascar. 9 Experimental induction of fluoroquinolone resistance in Y. pestis by exposure to nalidixic acid has been described. 10 Both the present and our previous 5 studies have utilized isolates of Y. pestis of southern African origin. These isolates are all the same biotype (orientalis), and ribotyping of five strains revealed two different ribotypes, one of which is typical of most third pandemic strains. A multicentre study of plague antimicrobials, utilizing a range of geographically and genetically diverse pathogen strains, is clearly 
